These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38058065)

  • 1. LncRNA
    Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
    Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Zhang G; Xiao Y; Tan J; Liu H; Fan W; Li J
    J Transl Med; 2024 Jun; 22(1):543. PubMed ID: 38844930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of circular RNA septin 9 inhibits the malignant progression of breast cancer by reducing the expression of solute carrier family 1 member 5 in a microRNA-149-5p-dependent manner.
    Wang J; Yang K; Cao J; Li L
    Bioengineered; 2021 Dec; 12(2):10624-10637. PubMed ID: 34738502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circ_0000463 contributes to the progression and glutamine metabolism of non-small-cell lung cancer by targeting miR-924/SLC1A5 signaling.
    Liu Y; Wang S; Pan S; Yan Q; Li Y; Zhao Y
    J Clin Lab Anal; 2022 Jan; 36(1):e24116. PubMed ID: 34811815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TEAD1 (TEA Domain Transcription Factor 1) Promotes Smooth Muscle Cell Proliferation Through Upregulating SLC1A5 (Solute Carrier Family 1 Member 5)-Mediated Glutamine Uptake.
    Osman I; He X; Liu J; Dong K; Wen T; Zhang F; Yu L; Hu G; Xin H; Zhang W; Zhou J
    Circ Res; 2019 Apr; 124(9):1309-1322. PubMed ID: 30801233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
    Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circ_0062558 promotes growth, migration, and glutamine metabolism in triple-negative breast cancer by targeting the miR-876-3p/SLC1A5 axis.
    Yuan M; Zhang J; He Y; Yi G; Rong L; Zheng L; Zhan T; Zhou C
    Arch Gynecol Obstet; 2022 Nov; 306(5):1643-1655. PubMed ID: 35284960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
    Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
    J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circ_0001273 downregulation inhibits the growth, migration and glutamine metabolism of esophageal cancer cells via targeting the miR-622/SLC1A5 signaling axis.
    Wu B; Chen Y; Chen Y; Xie X; Liang H; Peng F; Che W
    Thorac Cancer; 2022 Jun; 13(12):1795-1805. PubMed ID: 35567340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
    Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway.
    Pan Y; Han M; Zhang X; He Y; Yuan C; Xiong Y; Li X; Zeng C; Lu K; Zhu H; Lu X; Liu Q; Liang H; Liao Z; Ding Z; Zhang Z; Chen X; Zhang W; Zhang B
    Cell Oncol (Dordr); 2022 Feb; 45(1):163-178. PubMed ID: 35089546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated machine learning screened glutamine metabolism-associated biomarker SLC1A5 to predict immunotherapy response in hepatocellular carcinoma.
    Zhang G; Xiao Y; Liu H; Wu Y; Xue M; Li J
    Immunobiology; 2024 Sep; 229(5):152841. PubMed ID: 39096658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
    Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
    Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tRNA Gm18 methyltransferase TARBP1 promotes hepatocellular carcinoma progression via metabolic reprogramming of glutamine.
    Shi X; Zhang Y; Wang Y; Wang J; Gao Y; Wang R; Wang L; Xiong M; Cao Y; Ou N; Liu Q; Ma H; Cai J; Chen H
    Cell Death Differ; 2024 Sep; 31(9):1219-1234. PubMed ID: 38867004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells.
    Wang W; Pan H; Ren F; Chen H; Ren P
    Biosci Rep; 2022 Mar; 42(3):. PubMed ID: 35237783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circ_0000069 contributes to the growth, metastasis and glutamine metabolism in renal cell carcinoma (RCC) via regulating miR-125a-5p-dependent SLC1A5 expression.
    Yang L; Wang L; Wu J; Wang Y
    Transpl Immunol; 2023 Apr; 77():101764. PubMed ID: 36462557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma.
    Kawakami I; Yoshino H; Fukumoto W; Tamai M; Okamura S; Osako Y; Sakaguchi T; Inoguchi S; Matsushita R; Yamada Y; Tatarano S; Nakagawa M; Enokida H
    Biochem Biophys Res Commun; 2022 Jun; 611():99-106. PubMed ID: 35487063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reprogramming of Glutamine Amino Acid Transporters Expression and Prognostic Significance in Hepatocellular Carcinoma.
    Tambay V; Raymond VA; Voisin L; Meloche S; Bilodeau M
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
    J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
    van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
    Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.